Dyslipidemia in Type 2 Diabetes

This study has been completed.

First Received on October 19, 2007. No Changes Posted

Sponsor:	Merck
Information provided by:	Merck
ClinicalTrials.gov Identifier:	NCT00547274

Purpose

The purpose of the study is to compare the lipid-altering effects of MK0767, glipizide, and pioglitazone after 12 weeks of treatment.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Condition	Intervention	Phase
Diabetes Mellitus, Type II Dyslipidemia	Drug: MK0767	Phase III

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment

Resource links provided by NLM:

Genetics Home Reference related topics: 6q24-related transient neonatal diabetes mellitus

MedlinePlus related topics: Diabetes Diabetes Type 2

U.S. FDA Resources

Further study details as provided by Merck:

Study Start Date:	May 2003
Study Completion Date:	May 2004

Eligibility

Ages Eligible for Study:	21 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Men and non-pregnant females
Age greater than or equal to 21 years
Stop current diabetes therapy (if applicable)
Stop current statin therapy (if applicable)

Exclusion Criteria:

History of type 1 diabetes mellitus or ketoacidosis who are currently being treated with insulin
Patients on a weight loss program with ongoing weight loss, or starting an intensive exercise program within the last four weeks
Patients requiring treatment with corticosteroids for more than 14 consecutive days
Patients taking warfarin or warfarin-like anti-coagulants
Patients undergoing surgery within 30 days of Visit 1
Patients with Hepatitis B, Hepatitis C, active liver or gallbladder disease
Patients with history of pancreatitis or uncontrolled high blood pressure

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00547274

Sponsors and Collaborators

Merck

Investigators

Study Director:

Medical Monitor

Merck

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00547274 History of Changes
Other Study ID Numbers:	2007_635
Study First Received:	October 19, 2007
Last Updated:	October 19, 2007
Health Authority:	United States: Food and Drug Administration

Additional relevant MeSH terms:

Diabetes Mellitus
Diabetes Mellitus, Type 2
Dyslipidemias
Glucose Metabolism Disorders

Metabolic Diseases
Endocrine System Diseases
Lipid Metabolism Disorders

ClinicalTrials.gov processed this record on February 09, 2012